The Effect of Methylsulfonylmethane (MSM) on Cardiometabolic Health
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 试验地点
- 2
- 主要终点
- Change from baseline blood glucose at 4, 8, and 16 weeks
研究概览
简要总结
Obesity- related diseases are linked to elevated levels of inflammation, oxidative stress, and metabolic dysfunction. Methylsulfonylmethane (MSM) is a naturally occurring compound that demonstrates antioxidant and anti-inflammatory effects. Improvements in measures of metabolic health have been observed in mouse models of obesity and type 2 diabetes following MSM treatment. However, the effect of MSM on obesity-related risk factors for disease in humans has not been investigated. Therefore, the purpose of this investigation will be to determine whether MSM supplementation improves metabolic health, and markers of inflammation and oxidative status.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •overweight or obese adults without any diagnosed disease or current medications other than birth control. Participants must agree to maintain diet and physical activity levels throughout study.
排除标准
- •normal weight adults, or overweight/obese adults that do not meet the criteria for metabolically unhealthy obesity. Individuals currently on medications, or with diagnosed disease. Pregnant or nursing women, or women planning to become pregnant within the study timeframe. Lack of access to reliable transportation to study site, lack of internet access, or non-english speaking.
结局指标
主要结局
Change from baseline blood glucose at 4, 8, and 16 weeks
时间窗: 0,4,8,16 weeks
Change from baseline blood pressure at 4, 8, and 16 weeks
时间窗: 0,4,8,16 weeks
Change from baseline blood cholesterol at 4, 8, and 16 weeks
时间窗: 0,4,8,16 weeks
次要结局
- Change from baseline in waist circumference at 4, 8, and 16 weeks(0,4,8,16 weeks)
- Change from baseline resting metabolic rate at 16 weeks(0 and 16 weeks)
- Change from baseline percent body fat at 4, 8, and 16 weeks(0,4,8,16 weeks)
- Change from baseline insulin at 4, 8, and 16 weeks(0,4,8,16 weeks)
- Change from baseline in blood markers of inflammation and oxidative stress at 4, 8, and 16 weeks(0,4,8,16 weeks)
- Change from baseline in pulmonary function tests(0, 4, 8, 16 weeks)
研究者
Lindsey Miller
Assistant Professor
Washington State University